

**Supplementary Table 1 Clinical and pathological characteristics of RGC according to the subtypes of GC**

<b>Variables</b>	<b>EBV n = 9 (%)</b>	<b>MSI n = 9 (%)</b>	<b>GS n = 1 (%)</b>	<b>CIN n = 21 (%)</b>	<b>p</b>
<b>Sex</b>					0.627
Female	0 (0)	1 (11.1)	0 (0)	4 (19)	
Male	9 (100)	8 (88.9)	1 (100)	17 (81)	
<b>Age (1st surgery) (years)</b>					0.768
Mean (SD)	35.4 (12.8)	38.7 (19.5)	26.3	33.9 (13.7)	
<b>First surgery</b>					0.402
Peptic ulcer	9 (100)	7 (77.8)	1 (100)	19 (90.5)	
Adenocarcinoma	0 (0)	2 (22.2)	0 (0)	2 (9.5)	
<b>Type or Reconstruction</b>					0.728
Billroth II	9 (100)	8 (88.9)	1 (100)	20 (95.2)	
Roux-en-Y	0 (0)	1 (11.1)	0 (0)	1 (4.8)	
<b>Time between 1st and 2nd surgery (years)</b>					0.737
Mean (SD)	34.9 (8.7)	30 (16.8)	40.2	34.7 (11.8)	
<b>Age (years)</b>					0.935
Mean (SD)	70.4 (7.6)	69.7 (11.3)	66.5	68.7 (6.3)	
<b>BMI (Kg/cm<sup>2</sup>)</b>					0.167
Mean (SD)	20.8 (4.0)	23.5 (3.9)	29.1	21.5 (4.0)	
<b>Albumin (g/dL)</b>					0.772
Mean (SD)	3.5 (0.8)	3.8 (0.5)	4.0	3.8 (0.6)	
<b>Hemoglobin (g/dL)</b>					0.408
Mean (SD)	10.5 (2.1)	9.5 (2.5)	10.6	10.9 (2.0)	
<b>Charlson–Deyo Comorbidity Index (CCI)</b>					0.229
0 - 1	6 (66.7)	5 (55.6)	0 (0)	17 (81)	
>1	3 (33.3)	4 (44.4)	1 (100)	4 (19)	
<b>ASA classification</b>					0.334
I/II	8 (88.9)	5 (55.6)	1 (100)	18 (85.7)	
III/IV	1 (11.1)	4 (44.4)	0 (0)	3 (14.3)	
<b>Tumor size</b>					0.608
Mean (SD)	6.2 (3.2)	5.8 (2.6)	1.5	5.4 (3.7)	
<b>Lauren’s type</b>					0.083
Intestinal	3 (33.3)	3 (33.3)	1 (100)	15 (71.4)	
Diffuse/mixed	6 (66.7)	6 (66.7)	0 (0)	6 (28.6)	
<b>Grade of histological differentiation</b>					0.105
Well/moderately differentiated	2 (22.2)	3 (33.3)	1 (100)	13 (61.9)	
Poorly differentiated	7 (78.8)	6 (66.7)	0 (0)	8 (38.1)	
<b>Lymphatic invasion</b>					0.120

No	6 (66.7)	2 (22.2)	0 (0)	12 (57.1)	
Yes	3 (33.3)	7 (77.8)	1 (100)	9 (42.9)	
<b>Venous invasion</b>					<b>0.918</b>
No	7 (77.8)	6 (66.7)	1 (100)	16 (76.2)	
Yes	2 (22.2)	3 (33.3)	0 (0)	5 (23.8)	
<b>Perineural Invasion</b>					<b>0.105</b>
No	2 (22.2)	3 (33.3)	1 (100)	13 (61.9)	
Yes	7 (77.8)	6 (66.7)	0 (0)	8 (38.1)	
<b>Number of Lymph nodes</b>					<b>0.269</b>
Mean (SD)	26 (10.2)	29.3 (15.3)	13	20.3 (13.7)	
<b>pT</b>					<b>0.338</b>
T1/T2	2 (22.2)	2 (22.2)	1 (100)	9 (42.9)	
T3/T4	7 (77.8)	7 (77.8)	0 (0)	12 (57.1)	
<b>pN</b>					<b>0.827</b>
N0	5 (55.6)	4 (44.4)	1 (100)	9 (42.9)	
N+	4 (44.4)	5 (55.6)	0 (0)	12 (57.1)	
<b>pTNM</b>					<b>0.810</b>
I/II	6 (66.7)	4 (44.4)	1 (100)	13 (61.9)	
III/IV	3 (33.3)	5 (55.6)	0 (0)	8 (38.1)	
<b>Epstein-Barr virus (EBV)</b>					<b>—</b>
Negative	0 (0)	9 (100)	1 (100)	21 (100)	
Positive	9 (100)	0 (0)	0 (0)	0 (0)	
<b>MSI/MSS status</b>					<b>—</b>
MSS	7 (77.8)	0 (0)	1 (100)	21 (100)	
MSI	2 (22.2)	9 (100)	0 (0)	0 (0)	
<b>E-cadherin</b>					<b>—</b>
Normal	6 (66.7)	8 (88.9)	0 (0)	21 (100)	
Loss of expression	3 (33.3)	1 (11.1)	1 (100)	0 (0)	
<b>P53 status</b>					<b>0.044</b>
Normal	5 (55.6)	1 (11.1)	1 (100)	13 (61.9)	
Aberrant	4 (44.4)	8 (88.9)	0 (0)	8 (38.1)	

---

SD: standard deviation, BMI: body mass index, ASA: American Society of Anesthesiologists, MSI: microsatellite instability, MSS: microsatellite stable. P-values in bold are statistically significant